DAPA-CKD: Renal benefits of SGLT2 inhibition in people with and without diabetes | Hiddo Heerspink

(8:14)

DAPA CKD - trial

(9:32)

DAPA-CKD: Does confirmed renoprotection make the case for first-line SGLT2 inhibition? | Luigi Gnudi

(6:11)

ESC TV at ESC Congress 2020 - DAPA-CKD (Discussant)

(2:17)

ESC 2020 Discussion: The DAPA-CKD Study — Prof David Wheeler \u0026 Dr Harriette Van Spall

(13:17)

Diagnosing Chronic Kidney Disease- Renal Biomarkers and Diagnostic Tests

(1:1:11)

DAPA CKD Trial

(2:53)

SGLT2 Inhibitors: Can these drugs slow the progression of chronic kidney disease?

(49:14)

ESC 2020: Commentary on the DAPA-CKD Study — Dr Giuseppe Galati

(4:17)

Dapagliflozin clinically and cost effective in patients with chronic kidney disease DAPA CKD trial

(2:3)

CKD E-Learning - SGLT-2 inhibitors and CKD - 05.19.21

(46:1econd)

dapa ckd

(7:38)

Improving Renal Outcomes With Glucose-Lowering Therapy in the Individualized Management of T2DM

(19:55)

Nephrology Grand Rounds: SGLT2 Inhibitors

(58:38)

DAPA-CKD By Amr El-Husseini

(14:44)

KDIGO Diabetes Management in CKD Guideline

(24:32)

EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths

(1:52)

EMPA KIDNEY results: Flozins for all CKD with Dr Will Herrington

(1:6:22)

New Glucose-Lowering Drugs and Kidney Protection in CKD

(1:5:8)